Close

Biogen (BIIB) PT Raised to $360 at Oppenheimer as FDA Accepts Adu BLA with Priority Review

August 7, 2020 10:35 AM EDT Send to a Friend
Oppenheimer analyst Jay Olson raised the price target on Biogen (NASDAQ: BIIB) to $360.00 (from $325.00) while maintaining a Outperform ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login